Efetividade do tapentadol na dor oncológica - uma revisão sistemática

Introduction: A large proportion of people with cancer experience moderate to severe pain, being described as distressing or intolerable in more than a third of patients and presenting a negative correlation with quality of life. Inadequate pain control may be due to insufficient analgesi, adverse effects, or a combination of both. The adverse effects of strong opioids being particularly problematic, contributing to a substantial proportion of treatment failures resulting from poor therapeutic adherence. Long action Tapentadol, (TPD, is a centrally acting analgesic with double mechanism: acting as µ receptor agonist and inhibiting noradrenaline reuptake.The lower affinity of TPD to µ receptors, contributes to a reduction in the adverse effects that occur with classic strong opioids, maintaining a similar analgesic efficacy. Aim: Carry out a systematic review of the literature in order to identify the effectiveness of tapentadol in the control of moderate to severe cancer pain. Materials and Methods: Data collection and extraction was performed by the only reviewer, the investigator, using a standard form, suggested by the Cochrane Handbook for Systematic Reviews of Intervention, which allowed for the assessment of the risk of bias. The research was carried out according to the PRISMA method (Preferred Reporting Items for Systematic Reviews and Meta-Analysis), after excluding additional or unpublished publications on the International Test Registration Platform, using MEDLINE / Pubmed database and b-On platform. The study was carried out from April to May 2019, using the following health science descriptors: tapentadol and cancer pain, combined with each other through the Boolean operator “AND”, revealing a final sample of 5 articles. Results: It was possible to verify a positive action of tapentadol in the control of moderate to severe cancer pain, associated with a profile of greater tolerability. Conclusion: This systematic review of the literature suggests that tapentadol can be considered an effective and well-tolerated alternative for the treatment of moderate to severe cancer pain, but the poor expressiveness of the studies evaluated did not allow drawing other conclusions, requiring more robust studies.